VECTARION 50 Milligram Tablets

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Buy It Now

Active ingredient:

ALMITRINE BISMESYLATE

Available from:

Servier Laboratories (Ireland) Ltd

INN (International Name):

ALMITRINE BISMESYLATE

Dosage:

50 Milligram

Pharmaceutical form:

Tablets

Prescription type:

Product subject to prescription which may be renewed (B)

Authorization status:

Withdrawn

Authorization date:

2009-11-12

Summary of Product characteristics

                                PART II
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Vectarion 50 mg Film-coated tablets.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 50 mg of Almitrine Bismesylate.
For excipients, see 6.1.
3 PHARMACEUTICAL FORM
Film- coated tablets.
White, convex rod-shaped, tablets with a score mark on each surface.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Chronic obstructive lung disease and respiratory failure associated with hypoxaemia.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Oral route.
The usual daily dose is 50 to 100 mg (1 to 2 tablets daily), divided into two doses. Absorption is improved if drug is
taken with food. Balanced oxygen therapy may be administered simultaneously.
On the basis of experience to date it is recommended that after an initial 3 month treatment period, there should be an
interval of one month without treatment. This can then be followed by a maintenance regime of two months on
treatment and one month off treatment.
It is also recommended that the dose should be adjusted in relation to the patient's weight, the severity of the blood gas
abnormality and the incidence of adverse reactions as follows:
_Weight_
For patients weighing less than 50 kg, the dose should be reduced to 1 tablet per day.
_Blood gases_
Occasionally the severity of the modification of these parameters warrants the dose to be increased to 3 or 4 tablets
daily, but this should be undertaken for short periods of time only.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 25/09/2007_
_CRN 2041442_
_page number: 1_
4.3 CONTRAINDICATIONS
Use in patients hypersensitive to any of the active ingredients.
Use during pregnancy, or lactation in women breast
                                
                                Read the complete document